R
Robert A. Wolfe
Researcher at University of Michigan
Publications - 247
Citations - 38083
Robert A. Wolfe is an academic researcher from University of Michigan. The author has contributed to research in topics: Transplantation & Hemodialysis. The author has an hindex of 89, co-authored 214 publications receiving 35460 citations. Previous affiliations of Robert A. Wolfe include University of Chicago & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric Transplant
Robert A. Wolfe,Valarie B. Ashby,Edgar L. Milford,Akinlolu O. Ojo,Robert E. Ettenger,Lawrence Y. Agodoa,Philip J. Held,Friedrich K. Port +7 more
TL;DR: In this paper, the authors conducted a longitudinal study of mortality in 228,552 patients who were receiving long-term dialysis for end-stage renal disease, and 46,164 were placed on a waiting list for transplantation, 23,275 of whom received a first cadaveric transplant between 1991 and 1997.
Journal ArticleDOI
Model for end-stage liver disease (MELD) and allocation of donor livers
Russell H. Wiesner,Erick B. Edwards,Richard B. Freeman,Ann M. Harper,Ray Kim,Patrick S. Kamath,Walter K. Kremers,John R. Lake,Todd K. Howard,Robert M. Merion,Robert A. Wolfe,Ruud A.F. Krom,Paul M. Colombani,Paige C. Cottingham,Stephen P. Dunn,John J. Fung,Douglas W. Hanto,Sue V. McDiarmid,John M. Rabkin,Lewis W. Teperman,Jeremiah G. Turcotte,Lynn Rothberg Wegman +21 more
TL;DR: Data suggest that the MELD score is able to accurately predict 3-month mortality among patients with chronic liver disease on the liver waiting list and can be applied for allocation of donor livers.
Journal ArticleDOI
Chronic renal failure after transplantation of a nonrenal organ.
Akinlolu O. Ojo,Philip J. Held,Friedrich K. Port,Robert A. Wolfe,Alan B. Leichtman,Eric W. Young,J.A Arndorfer,Laura L. Christensen,Robert M. Merion +8 more
TL;DR: The five-year risk of chronic renal failure after transplantation of a nonrenal organ ranges from 7 to 21 percent, depending on the type of organ transplanted, and is associated with an increase by a factor of more than four in the risk of death.
Journal ArticleDOI
Spectrum of cancer risk among US solid organ transplant recipients.
Eric A. Engels,Ruth M. Pfeiffer,Joseph F. Fraumeni,Bertram L. Kasiske,Ajay K. Israni,Jon J. Snyder,Robert A. Wolfe,Nathan P. Goodrich,A. Rana Bayakly,Christina A. Clarke,Glenn Copeland,Jack L. Finch,Mary Lou Fleissner,Marc T. Goodman,Amy R. Kahn,Lori Koch,Charles F. Lynch,Margaret M. Madeleine,Karen Pawlish,Chandrika Rao,Melanie Williams,David Castenson,Michael Curry,Ruth Parsons,Gregory Fant,Monica Lin +25 more
TL;DR: Standardized incidence ratios and excess absolute risks assessing relative and absolute cancer risk in transplant recipients compared with the general population to describe the overall pattern of cancer following solid organ transplantation are described.
Journal ArticleDOI
Delayed graft function: risk factors and implications for renal allograft survival.
TL;DR: Delayed function and early rejection episodes exerted an additive adverse effect on allograft survival and the deleterious impact of delayed function is comparatively more severe than that of poor HLA matching.